within Pharmacolibrary.Drugs.ATC.L;

model L01FX11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 7.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0046,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0025,
    k12             = 0.4,
    k21             = 0.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bermekimab is a recombinant human monoclonal antibody targeting interleukin-1 alpha (IL-1α). It has been investigated primarily for its anti-inflammatory and antitumor activity in diseases such as colorectal cancer and hidradenitis suppurativa. As of 2024, it is not broadly approved for general clinical use but has been studied in clinical trials.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters have not been reported in peer-reviewed published literature. Parameters below are estimated based on standard monoclonal antibody characteristics and reported clinical study dosing.</p><h4>References</h4><ol><li><p>Simpson, EL, et al., &amp; Lebwohl, MG (2024). Interleukin-1α inhibitor bermekimab in patients with atopic dermatitis: randomized and nonrandomized studies. <i>Archives of dermatological research</i> 316(8) 589–None. DOI:<a href=\"https://doi.org/10.1007/s00403-024-03319-z\">10.1007/s00403-024-03319-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39214920/\">https://pubmed.ncbi.nlm.nih.gov/39214920</a></p></li><li><p>El Sayed, H, et al., &amp; Davies, M (2016). A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. <i>Journal of vascular surgery</i> 63(1) 133–41.e1. DOI:<a href=\"https://doi.org/10.1016/j.jvs.2015.08.069\">10.1016/j.jvs.2015.08.069</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26433546/\">https://pubmed.ncbi.nlm.nih.gov/26433546</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX11;
